BioCryst Pharmaceuticals (United States)
BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a late stage biotech company that focuses on oral drugs for rare and serious diseases. BioCryst's antiviral drug peramivir was approved by FDA in December 2014. Derived from Wikipedia licensed CC-BY-SA.
Open Access statistics for BioCryst Pharmaceuticals (United States), United States, covering academic research published from 2000 to 2024. Read More.
Open Access Percentage
37%
Total
Publications
224
Total Open
Publications
82
Total
Citations
5.7K
Open Access
Percentage
37%
Total
Publications
224
Total Open
Publications
82
Total
Citations
5.7K
Breakdown
Publisher Open
15%
Both
15%
Other Platform Open
7%
Closed
63%
Percentage of Open Access over time
Publisher Open
Both
Other Platform Open
Closed
Volume of Open Access over time
Open
Closed
Publisher Open
OA Journal 46%
31
Hybrid 13%
9
No Guarantees 41%
28
Other Platform Open
Domain 60%
31
Other Internet 37%
19
Institution 21%
11
Public 2%
1
Preprint 0%
0
Other Platform Locations
Name | Platform Type | Publications |
|---|---|---|
PubMed Central | Domain | 31 |
DOI | Other Internet | 18 |
Washington University in St. Louis | Institution | 3 |
Goethe University Frankfurt | Institution | 3 |
University of Southern Denmark | Institution | 2 |
Europe PMC | Domain | 2 |
Virginia Tech | Institution | 1 |
Unknown Repository | Other Internet | 1 |
University of Milan | Institution | 1 |
uj.edu.pl OAI-PMH Repository | Institution | 1 |